title: New drugs 2002. Part II.
authors.affiliation: Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, Philadelphia, Pa., USA.
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Hussar
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology / Q000627:therapeutic use; D000074323:Alemtuzumab; D000736:Androstenes / Q000494:pharmacology / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology / Q000627:therapeutic use; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D000077336:Caspofungin; D017277:Drug Approval; D004358:Drug Therapy; D054714:Echinocandins; D004983:Ethanolamines / Q000494:pharmacology / Q000627:therapeutic use; D000068759:Formoterol Fumarate; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D000068877:Imatinib Mesylate; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000494:pharmacology / Q000627:therapeutic use; D055666:Lipopeptides; D008666:Metalloendopeptidases / Q000494:pharmacology / Q000627:therapeutic use; D010446:Peptide Fragments / Q000494:pharmacology / Q000627:therapeutic use; D010455:Peptides; D010456:Peptides, Cyclic; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011092:Polyethylene Glycols; D045167:Progesterone Congeners / Q000494:pharmacology / Q000627:therapeutic use; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000318:Adrenergic beta-Agonists; D000736:Androstenes; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000925:Anticoagulants; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001549:Benzamides; D054714:Echinocandins; D004983:Ethanolamines; D006629:Hirudins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D055666:Lipopeptides; D010446:Peptide Fragments; D010455:Peptides; D010456:Peptides, Cyclic; D010879:Piperazines; D045167:Progesterone Congeners; D011743:Pyrimidines; D011994:Recombinant Proteins; C096323:rimabotulinumtoxinB; D000074323:Alemtuzumab; D011092:Polyethylene Glycols; D000068877:Imatinib Mesylate; D008666:Metalloendopeptidases; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A; D000077336:Caspofungin; C417083:peginterferon alfa-2b; C035144:drospirenone; C100416:peginterferon alfa-2a; C074619:bivalirudin; D000068759:Formoterol Fumarate